Efficacy and safety of currently marketed antiosteoporosis medications

J. Y. Reginster, A. Neuprez, N. Dardenne, C. Beaudart, P. Emonts, O. Bruyere

Résultats de recherche: Contribution à un journal/une revueArticle de revueRevue par des pairs

11 Téléchargements (Pure)

Résumé

During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally at all skeletal sites (i.e. spine, hip, and other nonspine). The armamentarium against osteoporosis includes antiresorptive agents (i.e. bisphosphonates, selective estrogen receptor modulators and denosumab), bone-forming agents (i.e. peptides from the parathyroid hormone family) and one agent with a dual mechanism of action (i.e. strontium ranelate). All these medications combine antifracture efficacy with a reasonable benefit/risk profile. However, the choice of a particular chemical entity, in one individual patient is based on the knowledge and expertise of the physician. Prioritization of drugs should be based on the individual profile of the patient, the severity of osteoporosis and the specific contraindications, warnings and precautions of use of the various available medications.

langue originaleAnglais
Pages (de - à)809-834
Nombre de pages26
journalBest Practice and Research: Clinical Endocrinology and Metabolism
Volume28
Numéro de publication6
Les DOIs
Etat de la publicationPublié - 2014
Modification externeOui

Empreinte digitale

Examiner les sujets de recherche de « Efficacy and safety of currently marketed antiosteoporosis medications ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation